Connect Biopharma Holdings (CNTB) Share-based Compensation (2024 - 2026)

Connect Biopharma Holdings has disclosed Share-based Compensation across 3 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 32.6% year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $4.3 million (down 19.24% YoY), while the FY2025 annual figure was $3.7 million, down 44.62% from the prior year.
• Share-based Compensation came in at $1.3 million for Q2 2026 at Connect Biopharma Holdings, up from $1.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.0 million in Q3 2024 to a low of $916000.0 in Q3 2025.
• Average Share-based Compensation over 3 years is $1.3 million, with a median of $1.2 million recorded in 2026.
• Year-over-year, Share-based Compensation slumped 54.7% in 2025 and jumped 32.6% in 2026.
• Over 3 years, Share-based Compensation stood at $1.4 million in 2024, then slumped by 34.55% to $917000.0 in 2025, then soared by 37.51% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.3 million in Q2 2026, $1.2 million in Q1 2026, and $917000.0 in Q4 2025.